The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Insight into Clinical Trials for Lupus

Insight into Clinical Trials for Lupus

June 12, 2019 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO—When Richard Furie, MD, was first asked to speak about lupus at the 2019 ACR State-of-the-Art Clinical Symposium, held April 5–7, organizers suggested he discuss low disease activity and classification criteria.

You Might Also Like
  • AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
  • Mitigate Risk and Increase Success of Lupus Clinical Trials
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
Also By This Author
  • Immune System Targeted for Research into New Rheumatoid Arthritis Treatments

But Dr. Furie, a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, N.Y., and a veteran investigator of lupus clinical trials, suggested another topic: new therapies. At the time, he expected a new drug would soon be approved, which would have been big news for lupus.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Unfortunately, the drug, anifrolumab, failed in the first of two phase 3 trials, becoming yet another in a series of disappointments. No new therapies for lupus have resulted from randomized, controlled trials since belimumab was approved in 2011.

In his talk, Dr. Furie addressed clinical trials, convinced that given the array of approaches and interest in finding better treatments, new therapies are bound to emerge.

Richard Furie, MD

“Lupus is being attacked in a very eclectic manner. It’s just fascinating to me how many different approaches are being taken to attack this condition,” he said.

Anifrolumab
The failure of the anifrolumab trial, TULIP-1, for which Dr. Furie was the principal investigator, was a particularly big letdown due to the drug’s target, the type 1 interferon pathway, and its early results. All five of the type 1 interferon subtypes bind to the same receptor, and anifrolumab is an antibody targeting that receptor.

“It actually would make a lot of sense to target the receptor, because then you’re blocking all type 1 interferons. Whereas, if you just target alpha interferon, for example, you have four other subtypes of the type 1 interferon that can signal through the receptor,” Dr. Furie said. “So one would expect greater interferon inhibition by targeting the type 1 receptor.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In a phase 2 trial, a subset of patients with the worst skin disease had an odds ratio of 3:7, depending on the dose and time point, for at least a 50% improvement on the CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index)—results that Dr. Furie called “remarkable.” High hopes for the drug’s effects surrounded not just its potential cutaneous effects, but also musculoskeletal and overall benefits, he said.1

In August 2018, manufacturer AstraZeneca announced the drug had failed its primary endpoint in TULIP-1.2 The results of a second trial, TULIP-2, have not yet been released.

“It really shocked the lupus community, because we had great expectations for this particular drug,” Dr. Furie said. “There have been a lot of analyses performed to find out why it failed.” Those findings and results of a companion phase 3 study will likely be out soon, he noted.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: 2019 State-of-the-Art Clinical Symposium, anifrolumab, clinical trials, Lupus, systemic lupus erythematosus (SLE), Treatment

You Might Also Like:
  • AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
  • Mitigate Risk and Increase Success of Lupus Clinical Trials
  • Lupus Expert Calls for Better Research, Outcomes of Clinical Trials
  • Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.